Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986325 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort J1 | EXPERIMENTAL | - |
| Cohort J2 | EXPERIMENTAL | - |
| Cohort J3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986325 | DRUG | Specified dose on specified days |
| Placebo | DRUG | Specified dose on specified days |
Inclusion Criteria: * Participants must be ethnically Japanese (both biological parents are ethnically Japanese). * Healthy male and female participants as determined by no clinically significant deviation from normal in medical history, physical examination, 12-lead ECGs, or clinical laboratory de...
BMS-986325 is an investigational small molecule being studied in healthy volunteers. It is being evaluated for safety, tolerability, drug levels, and drug effects in a Phase 1 clinical trial. The drug is not approved for any indication and is still in early clinical development.
BMS-986325 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical trials to evaluate the drug's safety and tolerability in healthy participants.
BMS-986325 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial is completed and was designed to assess safety, tolerability, drug levels, and drug effects in healthy volunteers.
BMS-986325 has one completed clinical trial, NCT05813717, which evaluated the safety, tolerability, drug levels, and drug effects of the drug in healthy Japanese participants. The trial enrolled 25 participants and was conducted in the United States.
BMS-986325 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial focused on healthy volunteers to assess safety and tolerability, and the drug has not yet progressed to later-stage trials or regulatory review.